Search research articles
Contact Us
Filters
Showing results (11-20 of 26) with videos related to
Page
of 3
Sort By:
British Journal of Cancer
|
May 9, 2013
Patients' and oncologists' views on the treatment and care of advanced ovarian cancer in the U.K.: results from the ADVOCATE study
V Jenkins, S Catt, S Banerjee, et al.
British Journal of Cancer
|
February 7, 2013
Targeted anti-vascular therapies for ovarian cancer: current evidence
M Hall, C Gourley, I McNeish, et al.
Anticancer Research
|
April 12, 2003
Is there a relationship between HLA type and prognostic factors in breast cancer?
C Gourley, C Thornton, C Massie, et al.
British Journal of Cancer
|
September 20, 2012
Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer
G Smith, M T H Ng, L Shepherd, et al.
ESMO Open
|
July 27, 2025
Genetic testing for BRCA1/2 variants in Northern African women with ovarian and breast cancers: a multicentre study of an under-represented ancestry
K S Shohdy, L Kassem, T Elnahas, et al.
American Journal of Physical Anthropology
|
April 1, 1985
Markers of genetic variation among the Waorani Indians of the Ecuadorian Amazon headwaters
J W Larrick, J Yost, C Gourley, et al.
BJOG : an International Journal of Obstetrics and Gynaecology
|
April 15, 2020
Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data
A Irodi, T Rye, K Herbert, et al.
International Journal of Oncology
|
May 5, 2005
WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear
C Gourley, A J W Paige, K J Taylor, et al.
The Science of the Total Environment
|
July 27, 2012
Determinants of polychlorinated dibenzo-p-dioxins and polychlorinated dibenzofurans in house dust samples from four areas of the United States
N C Deziel, J R Nuckols, J S Colt, et al.
Targeted Oncology
|
May 13, 2016
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
J Mateo, V Moreno, A Gupta, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 26) with videos related to
Sort By:
Page
of 3
British Journal of Cancer
|
May 9, 2013
Patients' and oncologists' views on the treatment and care of advanced ovarian cancer in the U.K.: results from the ADVOCATE study
V Jenkins, S Catt, S Banerjee, et al.
British Journal of Cancer
|
February 7, 2013
Targeted anti-vascular therapies for ovarian cancer: current evidence
M Hall, C Gourley, I McNeish, et al.
Anticancer Research
|
April 12, 2003
Is there a relationship between HLA type and prognostic factors in breast cancer?
C Gourley, C Thornton, C Massie, et al.
British Journal of Cancer
|
September 20, 2012
Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer
G Smith, M T H Ng, L Shepherd, et al.
ESMO Open
|
July 27, 2025
Genetic testing for BRCA1/2 variants in Northern African women with ovarian and breast cancers: a multicentre study of an under-represented ancestry
K S Shohdy, L Kassem, T Elnahas, et al.
American Journal of Physical Anthropology
|
April 1, 1985
Markers of genetic variation among the Waorani Indians of the Ecuadorian Amazon headwaters
J W Larrick, J Yost, C Gourley, et al.
BJOG : an International Journal of Obstetrics and Gynaecology
|
April 15, 2020
Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data
A Irodi, T Rye, K Herbert, et al.
International Journal of Oncology
|
May 5, 2005
WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear
C Gourley, A J W Paige, K J Taylor, et al.
The Science of the Total Environment
|
July 27, 2012
Determinants of polychlorinated dibenzo-p-dioxins and polychlorinated dibenzofurans in house dust samples from four areas of the United States
N C Deziel, J R Nuckols, J S Colt, et al.
Targeted Oncology
|
May 13, 2016
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
J Mateo, V Moreno, A Gupta, et al.
Page
of 3